[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[MoonLake Immunotherapeutics Class A Ordinary Shares](/topic/$mltx)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$mltx/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$mltx/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% no change  
**1 Month**: XX% -XX%  
**6 Months**: XX% -XX%  
**1 Year**: XX% -XX%  
**1-Year High**: XXX% on 2025-01-26  
**1-Year Low**: XX% on 2024-12-25  

**Most Supportive Themes**
- **Potential for a Buyout/Merger:** (35%) Speculation about a potential buyout by a larger pharmaceutical company, particularly Merck, is a recurring theme, fueled by insider buying activity.
- **Positive Technical Analysis/Squeeze Potential:** (25%) Some posts highlight potential for a short squeeze, with bullish technical analysis and mentions of institutional buying.
- **Focus on Psoriasis Pivot:** (15%) Optimism surrounding the company's potential pivot to psoriasis treatment, with some seeing the recent negative data as an opportunity.
  
**Most Critical Themes**
- **Concerns over Vela Phase X Study:** (50%)  The primary critical theme revolves around the failure of the sonelokimab drug to meet primary endpoints in the Vela phase X study for hidradenitis suppurativa.
- **Negative Data and Regulatory Pathway Uncertainty:** (30%)  Analysts are questioning the regulatory pathway and potential approval of the drug after it failed to meet primary endpoints.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXX      | XX% | XXXXX   | XX% | XX       | X% |
| TikTok  | XX       | X%  | X       | X%  | X        | X% |
| Reddit  | XX       | X%  | X       | X%  | X        | X% |
| YouTube | X        | X%  | X       | X%  | X        | X% |
|         |          |     |         |     |          |    |
| Total   | XXX      | XX% | XXXXX   | XX% | XX       | X% |